Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Eldon Mayer as a director, while Chuck Bramlage has left the board to focus on a newly accepted position as CEO at another start-up company.
Mr. Mayer is a pharmaceutical industry veteran with broad commercial experience, which spans over two decades in large pharma and specialty pharma across oncology, inflammatory disease, pulmonary disease, dermatology and rare diseases, with multiple successful exits by acquisition. He is currently EVP and chief commercial officer of Rigel Pharmaceuticals.
“His broad industry and operational background will be invaluable as we prepare for late stage clinical development and begin commercial planning across the entire Eiger pipeline,” he added.
